JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

Benzinga · 1d ago
JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.